ANI Pharmaceuticals (ANIP) Upgraded to “Buy” by ValuEngine

ValuEngine upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a buy rating in a report released on Friday morning.

A number of other research firms have also weighed in on ANIP. Canaccord Genuity set a $77.00 price objective on ANI Pharmaceuticals and gave the company a buy rating in a research note on Friday, December 29th. TheStreet raised ANI Pharmaceuticals from a c+ rating to a b rating in a research note on Thursday, November 16th. BidaskClub raised ANI Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, January 5th. Finally, Zacks Investment Research lowered ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, January 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of Hold and a consensus price target of $72.25.

Get ANI Pharmaceuticals alerts:

Shares of ANI Pharmaceuticals (NASDAQ:ANIP) opened at $62.69 on Friday. The firm has a market capitalization of $731.03, a P/E ratio of 17.76 and a beta of 2.75. ANI Pharmaceuticals has a 52 week low of $42.23 and a 52 week high of $74.70. The company has a debt-to-equity ratio of 1.13, a quick ratio of 2.39 and a current ratio of 3.36.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.06. The firm had revenue of $47.30 million during the quarter, compared to analyst estimates of $52.55 million. ANI Pharmaceuticals had a positive return on equity of 23.41% and a negative net margin of 0.61%. The business’s quarterly revenue was up 23.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.84 earnings per share. sell-side analysts forecast that ANI Pharmaceuticals will post 4.52 EPS for the current year.

A number of hedge funds have recently made changes to their positions in ANIP. Bank of Montreal Can lifted its stake in ANI Pharmaceuticals by 681.8% in the fourth quarter. Bank of Montreal Can now owns 2,408 shares of the specialty pharmaceutical company’s stock worth $156,000 after acquiring an additional 2,100 shares during the period. SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals in the third quarter worth $197,000. Millennium Management LLC purchased a new stake in ANI Pharmaceuticals in the fourth quarter worth $210,000. Violich Capital Management Inc. purchased a new stake in ANI Pharmaceuticals in the third quarter worth $217,000. Finally, Driehaus Capital Management LLC purchased a new stake in ANI Pharmaceuticals in the fourth quarter worth $220,000. 56.00% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/ani-pharmaceuticals-anip-upgraded-to-buy-by-valuengine/1908919.html.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.